Pyxis Oncology, an immuno-oncology company developing antibody drugs to restore activity to dysfunctional T cells, has appointed Ronald Herbst as its chief scientific officer. Herbst joins the Boston-based company from the AstraZeneca (NYSE: AZN) global biologics R&D arm, MedImmune, where he was vice president of research and development and head of oncology research.
Sponsored · Whitepaper
What the most successful life sciences fundraising pitch decks all have in common
Brex
From Our Editors · Special Report
Learn what's fueling San Diego's biotech investment and partnership opportunities
From Our Editors · Special Report
Top biotech and investment players offer their best plans and current progress in stemming and ultimately defeating the worldwide pandemic
